Treatment Begins Before the Flight
For an international patient, IVF in Istanbul does not begin at the airport or at the first hospital appointment.
It begins when the patient’s medical history is organised, reviewed, and converted into a realistic clinical pathway.
Without this preparation, international treatment can become a sequence of generic quotations, rushed travel decisions, repeated tests, and unexpected changes after arrival. A lower advertised price or an available appointment does not by itself mean that the patient is medically ready to begin.
Jinemed and IVF Turkey approach the international journey as a coordinated process connecting the patient, fertility physician, licensed treatment centre, embryology laboratory, nursing team, local healthcare providers, and international patient coordinator.
Each has a different responsibility. The physician makes clinical decisions. The licensed centre provides treatment. The coordinator helps information and appointments move safely between the patient and the medical team.
The purpose is not simply to bring a patient to Türkiye. It is to make sure that travel takes place for the right treatment, at the right time, with the right information.
Step One: Building the Medical File
The first review is only as useful as the information provided.
A strong international fertility file may include:
- Patient and partner ages
- Duration of infertility
- Menstrual-cycle history
- Previous pregnancies, births, ectopic pregnancies, and miscarriages
- AMH and other relevant hormone results
- Recent pelvic ultrasound and antral follicle count
- Semen analysis
- Previous IUI or IVF records
- Stimulation protocols and medication doses
- Egg-collection, fertilisation, and embryology reports
- Embryo-transfer and freezing records
- Genetic reports
- Surgical, hysteroscopy, or laparoscopy notes
- Medical conditions and current medication
- Cancer-treatment or fertility-preservation history where relevant
For patients with previous IVF failure, a short letter saying “three unsuccessful cycles” is not enough. The useful questions are how many follicles developed, how many eggs were mature, how fertilisation occurred, whether embryos reached blastocyst, what was transferred, and what happened after transfer.
Documents should be sent in readable form and arranged chronologically. When reports are not in Turkish or English, translation may be necessary for safe interpretation.
The coordinator can help identify missing documents, but should not interpret them as a physician.
Step Two: Medical Review Before a Treatment Promise
The medical file should be reviewed by the appropriate fertility physician before a final treatment recommendation is presented.
The review may conclude that:
- The patient appears suitable for IVF
- Additional tests are required before travel
- The male partner needs urologic assessment
- A uterine or surgical issue should be evaluated first
- Fertility preservation is more appropriate than immediate transfer
- PGT-M preparation must be completed before the IVF cycle
- Treatment can be partly monitored in the patient’s home country
- A full cycle should take place in Istanbul
- The expected benefit of further treatment is very limited
- The requested treatment is not medically indicated or is not legally available in Türkiye
This stage should distinguish what is known from what remains uncertain.
An online review cannot replace every examination. Ultrasound findings may need confirmation, ovarian response may differ from expectation, and the final medication plan may change after the first in-person assessment.
The patient should understand that a preliminary plan guides preparation; it is not a guarantee that every stage will proceed exactly as predicted.
Step Three: Confirming Legal and Clinical Availability
Assisted reproduction laws differ between countries.
Patients may contact Türkiye after researching donor eggs, donor sperm, donor embryos, surrogacy, social sex selection, or other services offered elsewhere. These options should not be advertised as available in Türkiye when Turkish law does not permit them.
Legal eligibility and medical suitability are separate questions. A procedure may be medically discussed in international literature but unavailable under national regulation. Another procedure may be legally available but unnecessary for the patient’s diagnosis.
Before flights, payment, or medication are arranged, the patient should receive a clear explanation of:
- Which treatment is legally available
- Which licensed centre will provide it
- Which physician is responsible
- Where eggs, sperm, and embryos will be handled
- Whether genetic testing or freezing is part of the plan
- Whether reproductive material can legally be transported across borders
Regulatory questions should be answered through current rules and licensed providers, not through assumptions based on another country’s practice.
Step Four: A Written Treatment Plan and Cost Outline
International treatment requires both medical and financial clarity.
A written plan should identify:
- Proposed treatment
- Expected menstrual-cycle timing
- Tests required before arrival
- Approximate length of stay
- Medication plan or estimate
- Monitoring schedule
- Egg-collection and anaesthesia arrangements
- Fertilisation method
- Expected embryo-culture approach
- Fresh transfer, freeze-all, or genetic-testing pathway when this can be anticipated
- Follow-up after returning home
The cost outline should separate:
- Hospital and clinical fees
- Medication
- ICSI
- Anaesthesia
- Embryo freezing and storage
- Genetic testing
- Surgical sperm retrieval
- Future frozen embryo transfer
- Travel, accommodation, local transport, and insurance
Every item should be identified as included, excluded, optional, or variable.
Some costs cannot be known with certainty before stimulation. Medication requirements vary, embryo freezing depends on development, and genetic fees may depend on the number of embryos or the complexity of a PGT-M case.
Transparency does not require pretending that nothing can change. It requires explaining what may change and why.
Step Five: Planning Around the Menstrual Cycle
IVF travel timing is linked to biology.
Many treatment cycles begin around the second day of menstruation, but the precise plan depends on the protocol. Menstrual dates can shift, follicle development may be faster or slower than expected, and egg collection cannot be guaranteed for a specific calendar day weeks in advance.
Patients should avoid non-refundable travel arrangements that leave no flexibility.
The team should discuss:
- When the patient should notify the coordinator that menstruation has begun
- Whether a baseline ultrasound is required before medication
- Whether medication begins at home or after arrival
- Which monitoring results must be shared
- How quickly flights can be changed
- What would delay or cancel the cycle
Travel planning should follow the medical schedule. The medical schedule should not be forced to fit a fixed holiday booking.
Full Treatment in Istanbul
For many international patients, the simplest pathway is to complete ovarian stimulation, monitoring, egg collection, laboratory procedures, and transfer planning in Istanbul.
A full fresh IVF cycle often requires approximately two to three weeks, although the exact stay varies. Patients with a short or long stimulation, delayed follicle growth, freeze-all plan, or additional procedures may need a different schedule.
Completing monitoring within the same clinical system can simplify communication because ultrasound, hormone results, medication adjustments, egg collection, and laboratory planning are coordinated directly.
This may be especially useful for complex cases, patients with previous poor response, significant medical history, or those who prefer the complete treatment under one team.
Split Treatment and Local Monitoring
Some patients cannot remain in Istanbul for the entire stimulation period. A split-treatment pathway may allow early monitoring to take place in the home country, followed by travel to Istanbul for the final stage, egg collection, and laboratory treatment.
For selected UK patients, early consultation and monitoring may be arranged through a suitable local fertility provider, including an associated London pathway where agreed in advance. The exact clinic, tests, fees, and responsibility for prescribing must be confirmed before the cycle begins.
A split pathway may include:
- Baseline ultrasound and antral follicle count
- AMH or other blood tests
- Prescription and medication planning
- Follicle-tracking scans
- Estradiol testing when requested
- Electronic transfer of results to the Istanbul team
- Travel once follicle development reaches the agreed stage
Split care reduces time abroad but increases the need for precise communication. Ultrasound measurements, laboratory units, report timing, medication changes, and time-zone differences must be managed carefully.
No patient should begin stimulation without knowing which doctor is prescribing, who reviews each scan, who authorises dose changes, and when travel is expected.
Arrival and First In-Person Assessment
After arrival, the patient’s identity, medical history, medication, and original records should be confirmed.
The first in-person assessment may include consultation, ultrasound, blood tests, infectious-disease screening, anaesthesia review, semen planning, and completion of consent forms.
This appointment is also the time to confirm:
- The treating physician
- Hospital and laboratory location
- Medication schedule
- Monitoring appointments
- Emergency contact route
- Estimated egg-collection window
- Sperm-sample or surgical-retrieval plan
- Communication method for laboratory updates
If the findings differ from the remote review, the plan may need to change. A lower follicle count, unexpected cyst, abnormal hormone result, fever, or sperm issue may alter timing or treatment.
Changing the plan for a medical reason is not a failure of coordination. Failing to explain the reason would be.
Ovarian Stimulation and Monitoring
During stimulation, medication encourages a group of follicles to develop.
Monitoring usually involves repeated ultrasound examinations and, when appropriate, hormone tests. The physician may adjust medication according to follicle number, growth pattern, hormone results, and risk of excessive or inadequate response.
International patients should know that monitoring determines the schedule. Egg collection cannot be safely timed from the menstrual calendar alone.
The coordinator can remind patients about appointments and relay approved instructions. Medication changes must come from the authorised clinical team.
Patients should receive clear guidance about symptoms requiring urgent review, including severe pain, heavy bleeding, fever, difficulty breathing, rapidly increasing abdominal swelling, or other concerns identified by the medical team.
Routine WhatsApp messaging is not a substitute for emergency medical services.
Planning for Sperm and Male-Factor Care
The sperm pathway should be organised before egg collection.
For straightforward cases, the male partner may provide a sample on the day of retrieval. When semen quality is severely impaired, previous samples have been inconsistent, or travel timing creates uncertainty, freezing a backup sample may be discussed.
Patients with azoospermia or planned TESE/micro-TESE require urologic review and coordination with the embryology laboratory. The team must decide whether sperm retrieval should occur before stimulation with freezing or be timed with egg collection.
The female partner should not complete stimulation only to discover on retrieval day that a known male-factor issue was never planned.
Genetic evaluation may also be necessary in selected cases of severe oligospermia or azoospermia.
Egg Collection
Egg collection is usually performed after a trigger medication given at a precisely scheduled time.
The procedure is commonly completed under sedation or anaesthesia using ultrasound guidance. Patients receive fasting instructions, consent information, and guidance about recovery.
After the procedure, the clinical team monitors pain, bleeding, blood pressure, and recovery from anaesthesia. Most patients leave the hospital the same day, but they should not drive and should follow the medical team’s activity and medication instructions.
The number of follicles seen before retrieval is not the same as the number of eggs collected. Not every follicle contains an egg, and not every egg is mature.
Clear expectations before the procedure can reduce the shock patients may experience when these numbers differ.
Fertilisation and Embryology Updates
After collection, eggs are assessed for maturity and fertilised using the planned laboratory method, often ICSI when medically indicated or part of the centre’s protocol.
Embryo development is then monitored over several days. Updates may include:
- Number of eggs collected
- Number of mature eggs
- Normal fertilisation
- Cleavage-stage development
- Blastocyst formation
- Embryos suitable for transfer, freezing, or biopsy
The communication schedule should be agreed in advance. Patients need to know whether updates come directly from an embryologist, physician, nurse, or coordinator relaying documented laboratory information.
Embryo numbers usually decrease through each biological stage. This attrition can be normal, but its extent cannot be predicted precisely.
No coordinator should independently grade embryos or promise that a particular embryo will become a pregnancy.
Fresh Transfer, Freeze-All, or Genetic Testing
The plan after egg collection depends on embryo development and the patient’s medical situation.
A fresh embryo transfer may be considered when the endometrium, hormone environment, embryo development, and clinical risk are appropriate.
A freeze-all strategy may be recommended when:
- There is concern about ovarian hyperstimulation syndrome
- Hormone levels or endometrial timing are not suitable
- Genetic testing is planned
- The patient requires additional uterine evaluation
- The medical team believes a later transfer is safer or more appropriate
Freezing all embryos is not evidence that the cycle failed. It may be an intentional part of treatment.
For PGT-M, the genetic laboratory may require case preparation before IVF, blood or DNA samples from relatives, and several weeks to establish the test. Embryos are usually biopsied and frozen while results are awaited, with a later visit for frozen embryo transfer if a suitable embryo is identified.
The patient should understand the possibility of returning home without a transfer and why that may be medically necessary.
Embryo Transfer
Embryo transfer is usually a brief procedure performed without anaesthesia, although individual circumstances vary.
Before transfer, the team confirms patient identity, embryo information, number of embryos planned, consent, and the clinical strategy. The decision should consider embryo quality, patient age, previous history, and the risks of multiple pregnancy.
After transfer, patients receive written instructions covering medication, activity, travel, warning symptoms, and pregnancy-test timing.
Bed rest does not guarantee implantation, and normal movement does not cause an embryo to fall from the uterus. Patients should follow evidence-based guidance rather than restrictive rituals that increase fear.
Travel home is often possible after a short interval, but the timing should be confirmed by the treating team, particularly after complications or significant symptoms.
Returning Home
The treatment relationship does not end when the patient leaves Istanbul.
Before departure, the patient should receive or know how to obtain:
- Medication instructions
- Procedure summary
- Egg, fertilisation, and embryo records
- Embryo-transfer report
- Information about frozen embryos and storage
- Genetic-testing plan where relevant
- Pregnancy-test date
- Guidance for urgent symptoms
- Contact route for medical questions
- Instructions for local follow-up
The local physician should understand what treatment occurred and which medications continue.
International patients should seek urgent care locally for severe pain, heavy bleeding, fainting, fever, breathing difficulty, or other emergency symptoms. Waiting for a reply from a clinic in another country can be unsafe.
Pregnancy Testing and Early Monitoring
The pregnancy blood test is performed on the date specified by the medical team, based on the transfer and embryo stage.
Testing too early can produce confusing results. Home urine tests may be affected by timing or previous trigger medication.
If the test is positive, repeat beta hCG measurement and early ultrasound may be requested to assess progression and confirm that the pregnancy is located within the uterus.
IVF Turkey and Jinemed can provide early instructions and review shared results, but ongoing pregnancy care should be established with an obstetric provider in the patient’s home country.
The transition should include medication guidance and an appropriate handover rather than leaving the patient to decide alone when fertility medication stops.
If the Result Is Negative
A negative result should not trigger an immediate sales conversation about another cycle.
The patient should receive acknowledgement of the outcome and an opportunity for medical review. The team may examine ovarian response, egg maturity, fertilisation, embryo development, transfer conditions, and whether any targeted change is justified.
Some failures do not reveal a specific correctable cause. The clinic should not create certainty by recommending every available add-on.
The patient may choose to repeat treatment, use frozen embryos, seek another opinion, pause, or stop. These decisions should be respected.
International follow-up is particularly important after a negative result because patients who have returned home may otherwise feel that communication ended when payment and procedures were completed.
Frozen Embryo Transfer and a Second Visit
Patients with frozen embryos may return for a frozen embryo transfer during a later cycle.
Endometrial preparation may occur through a natural-cycle or medication-supported pathway depending on cycle pattern, medical history, and physician recommendation.
Much of the monitoring may be completed locally when reliable ultrasound and laboratory support are available. The patient then travels to Istanbul near the expected transfer date.
The stay is usually shorter than a full IVF cycle, but travel should retain flexibility because endometrial development and progesterone timing determine the final date.
The team must confirm embryo stage, progesterone exposure, medication schedule, and travel plan precisely. In a blastocyst transfer, timing errors can affect synchronisation between the embryo and endometrium.
Medical Care and Travel Services Must Remain Distinct
International IVF includes practical needs: flights, accommodation, airport transport, local travel, translation, food, and time away from work.
These services can make treatment easier, but they must remain clearly separate from medical decision-making.
A hotel recommendation is not a medical prescription. A tour or travel schedule should never interfere with monitoring, medication, procedures, or recovery. IVF is often outpatient treatment, and many patients enjoy Istanbul between appointments, but tourism should not be presented as improving pregnancy outcomes.
Patients should know which organisation provides each service, who receives payment, what can be cancelled, and whom to contact if a non-medical problem occurs.
Clear separation protects the patient, clinical team, and travel provider.
Who Is Responsible for What?
A safe international pathway makes responsibility visible.
Treating Physician
- Reviews medical information
- Diagnoses and recommends treatment
- Prescribes and adjusts medication
- Performs or supervises clinical procedures
- Explains risks, alternatives, and prognosis
Licensed IVF Centre and Hospital
- Provides regulated clinical and laboratory care
- Maintains medical records and consent
- Performs monitoring, retrieval, fertilisation, culture, freezing, and transfer as applicable
- Manages clinical safety and complications within its services
Embryology Laboratory
- Handles eggs, sperm, and embryos
- Documents fertilisation and embryo development
- Performs freezing, warming, biopsy, and related laboratory procedures when indicated
- Maintains identification, witnessing, and quality systems
Nurse
- Provides approved medication and procedure guidance
- Supports monitoring and recovery
- Escalates symptoms or clinical concerns
International Patient Coordinator
- Helps collect records
- Organises communication and appointments
- Explains the agreed pathway and practical timing
- Relays documented instructions
- Directs clinical questions to authorised professionals
Travel or Health-Tourism Provider
- Supports agreed non-medical services
- Provides clear travel terms and costs
- Does not diagnose, prescribe, or replace the licensed clinical team
When these roles are blurred, errors and unrealistic expectations become more likely.
A Journey Built on Continuity
International IVF is not one procedure in another country. It is a chain of decisions stretching from the first medical record to pregnancy follow-up or review after an unsuccessful cycle.
The quality of the journey depends on every link:
- Accurate records
- Real medical review
- Legal clarity
- Transparent costs
- Flexible travel planning
- Safe monitoring
- Coordinated laboratory care
- Written instructions
- Local emergency access
- Follow-up after the patient returns home
Jinemed provides the clinical and institutional experience. IVF Turkey helps international patients navigate the pathway and communicate with the appropriate licensed teams. Neither medical expertise nor coordination is sufficient alone; the patient needs both to work together without confusing their responsibilities.
Treatment may take place in Istanbul, but care begins before arrival and continues after departure.